START NOW with the first and only treatment approved for both RMS and PPMS

Relapse reductions in RMS

Superior reductions in relapses vs Rebif in RMS in head-to-head trials

OCREVUS® (ocrelizumab) for PPMS

OCREVUS was proven in PPMS across key clinical and MRI measures of efficacy

Risk of disability progression in RMS

Significant reduction in risk of confirmed disability progression vs Rebif in RMS

OCREVUS®  (ocrelizumab) Dosing Schedule

OCREVUS is dosed once every 6 months

OCREVUS® (ocrelizumab) and MRI data

Near-complete suppression of T1 Gd+ lesions and superiority on T2 lesion endpoint vs Rebif in RMS*

OCREVUS® (ocrelizumab) Patient Support

Support to help patients start and stay on OCREVUS

Safety demonstrated in OPERA 1 and 2

Safety profile in OPERA I and II

Safety demonstrated in ORATORIO.

Safety profile in ORATORIO

*The precise mechanism by which OCREVUS exerts its therapeutic effects in MS is unknown. Gd+=gadolinium-enhancing.
The first dose of OCREVUS is administered as two 300 mg IV infusions given 2 weeks apart. Subsequent doses are administered as a single 600 mg infusion every 6 months.